Foundation Medicine ditches plans to raise $150M

The bearish market that led Lombard Medical to delay its IPO and TriVascular Technologies ($TRIV) to price below its range has scuttled a fundraise from diagnostics luminary Foundation Medicine ($FMI). The company pulled the plug on an effort to raise $150 million in a stock offering, citing "market conditions" in a filing with the SEC. The company raised $106 million in its IPO last year, and its shares are up about 44% since then. Filing | Initial S-1

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.